Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Beta-glucan cream added to standard skin care for IAD in hospitalized adults

Official title: Improving the Care of Incontinence-Associated Dermatitis (IAD) Using a Beta-Glucan Cream as a Hydrating and Soothing Agent

Run by University of Alberta · NCT07524439 · Data updated 2026-11-12

This study tests whether adding a 0.5% beta-glucan moisturizing cream to usual skin care helps adults with incontinence-associated dermatitis heal faster and feel better.

More Urinary Incontinence trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment60 (estimated)
SponsorUniversity of Alberta
Academic / other
Locations1 site (Edmonton, Alberta)
StatusRecruiting
StartedMay 1, 2026
Main results expectedMay 1, 2027
Study endsNovember 30, 2028
Registry record updatedJune 26, 2026
Trial IDNCT07524439 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) with IAD due to urinary and/or fecal incontinence and a hospital stay of at least 7 days.

Probably not a fit

Patients without IAD, with incontinence but no dermatitis, or with known hypersensitivity to cream components may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this interventional study, hospitalized adults with IAD will receive standard skin care with or without a 0.5% beta-glucan cream (Soothing Beta Cream) to see if the cream improves visible skin severity, accelerates healing, and reduces discomfort. The trial will compare outcomes using the Ghent Global IAD Monitoring Tool (GLOBIAD-M) and patient-reported symptoms. Safety and tolerability of the cream will also be monitored. Participants will be followed during their hospital stay, with assessments of skin condition and comfort.

Why it matters

Potential benefit: If successful, patients may experience faster healing, less redness and irritation, and improved comfort during care.

How similar studies have gone: Prior research in IAD management supports the potential benefit of moisturizers, though this specific beta-glucan formulation in hospitalized adults is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Eligible participants are adults (≥18 years) with IAD secondary to urinary and/or fecal incontinence and an expected hospital stay of ≥7 days. Written informed consent will be obtained directly or via substitute decision-maker. Exclusion criteria include absence of IAD or incontinence, pediatric patients, and participants with known hypersensitivities to components of cream (e.g. beta-glucan).

Where it's running

  • University of Alberta Hospital
    Edmonton, Alberta, Canada
    Recruiting

Study contacts

  • Principal investigator: Marlene Dytoc, MD/PhD — University of Alberta
  • Study coordinator: Eileen Tang, BSc
  • Email: eatang@ualberta.ca
  • Phone: 7802636245

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.